Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD99 and CD99L2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| CD99 Antigen | CD99 ECD-Fc Fusion Protein High purity (>95%), Endotoxin Controlled (<1 EU/µg). HEK293 Expressed for native O-glycosylation. Sequence Verified. |
View CD99 Products |
| CD99L2 Antigen | CD99L2 ECD-Fc Fusion Protein High purity (>95%), Endotoxin Controlled (<1 EU/µg). HEK293 Expressed. Sequence Verified. |
View CD99L2 Products |
| Gene Delivery | CD99 / CD99L2 Lentivirus Premade Particles Full-length ORF for stable cell line construction and flow cytometry validation. |
View CD99 Products |
| Benchmark Ab | Anti-CD99 Recombinant Reference Antibody Recombinant positive control derived from clinical/benchmark sequences. |
View CD99 Products |
| Validator | CD99 / CD99L2 siRNA Set Target-specific knockdown pool for functional specificity validation. |
View CD99 Products |
| Related Target A | PECAM1 (CD31) Synergistic endothelial junction molecule regulating leukocyte transendothelial migration. |
View PECAM1 Products |
| Related Target B | JAM1 (F11R) Co-regulator of tight junction integrity and leukocyte extravasation pathways. |
View F11R Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-family selectivity screening (CD99 vs. CD99L2) | Highly purified, sequence-verified human CD99 and CD99L2 ortholog proteins available. |
| Conformation-dependent binding analysis | HEK293 mammalian expression host ensures native post-translational O-glycosylation. |
| Lack of reliable positive controls | Sequence-verified clinical benchmark antibodies (biosimilars) included in our portfolio. |
| Off-target assay false positives | High-specificity siRNA validation sets for target knockdown confirmation. |
Live CD99 & CD99L2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CD99 and its paralogue CD99L2 is gaining traction across oncology and inflammatory immunology. Historically recognized as diagnostic markers for Ewing's sarcoma, these molecules are now being actively pursued as functional therapeutic targets. CD99 plays a pivotal role in maintaining the transendothelial migration (TEM) of leukocytes and tumor cell survival. CD99L2, sharing structural homology, similarly regulates leukocyte extravasation during inflammatory responses.
The race for CD99/CD99L2 therapeutics is intensifying, with major players shifting focus from traditional naked monoclonal antibodies to advanced antibody-drug conjugates (ADCs) and bispecific constructs. As first-generation therapies targeting hematological malignancies and Ewing's sarcoma reach clinical validation, the next wave of R&D is targeting the selective blockade of CD99/CD99L2 in inflammatory diseases and overcoming resistance mechanisms in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Academic Institutes, Biotech Consortia | Ewing's Sarcoma, AML | Internalization Assay (Need high-purity, glycosylation-native ECD-Fc) |
| Bispecific Antibodies | Oncology Biopharma | Myelodysplastic Syndromes (MDS) | Dual-targeting validation (Need highly purified CD99 and CD99L2 panels) |
| Monoclonal Antibodies (Blocking) | Immunology Research Groups | Inflammatory Bowel Disease, Ischemia | Transendothelial Migration assays (Need Lentivirus for stable cell lines) |